Cargando…

Stratification of brachytherapy-treated intermediate-risk prostate cancer patients into favorable and unfavorable cohorts

PURPOSE: To evaluate biochemical failure (BF) and prostate cancer specific mortality (PCSM) in intermediate-risk (IR) brachytherapy patients stratified into favorable and unfavorable cohorts, and to compare those outcomes to patients with low (LR) and high-risk (HR) disease. MATERIAL AND METHODS: Fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merrick, Gregory S., Butler, Wayne M., Galbreath, Robert W., Fiano, Ryan, Adamovich, Edward
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2015
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716130/ https://www.ncbi.nlm.nih.gov/pubmed/26816337 http://dx.doi.org/10.5114/jcb.2015.56763

Ejemplares similares

Prostate cancer-specific death in brachytherapy treated high-risk patients stratified by pre-treatment PSA
por: Merrick, Gregory S., et al.
Publicado: (2017)

Does supplemental external beam radiation therapy impact urinary, bowel, and erectile function following permanent prostate brachytherapy?: results of two prospective randomized trials
por: Merrick, Gregory S., et al.
Publicado: (2017)

Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy
por: Taira, Al V., et al.
Publicado: (2014)

The impact of age on prostate cancer progression and quality of life in active surveillance patients
por: Merrick, Gregory S., et al.
Publicado: (2020)

Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment
por: Taira, Al V., et al.
Publicado: (2013)

Permanent prostate brachytherapy extracapsular radiation dose distributions: analysis of a multi-institutional database
por: Merrick, Gregory S., et al.
Publicado: (2013)

Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

CT-PLANNED transperineal prostate BIOPSY IN patients without a rectum
por: Merrick, Gregory S., et al.
Publicado: (2020)

Effect of the timing of hydrogel spacer placement on prostate and rectal dosimetry of low-dose-rate brachytherapy implants
por: Butler, Wayne M., et al.
Publicado: (2021)

Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting
por: Taira, A V, et al.
Publicado: (2009)

cExternal beam radiation results in minimal changes in post void residual urine volumes during the treatment of clinically localized prostate cancer
por: Orio, Peter F, et al.
Publicado: (2009)

Grade and stage misclassification in intermediate unfavorable‐risk prostate cancer radiotherapy candidates
por: Sorce, Gabriele, et al.
Publicado: (2022)

Granulations and Differential Diagnosis of Cases Favorable and Cases Unfavorable
por: Hinman, Thomas P.
Publicado: (1921)

Effect of Androgen Deprivation on Long-term Outcomes of Intermediate-Risk Prostate Cancer Stratified as Favorable or Unfavorable: A Secondary Analysis of the RTOG 9408 Randomized Clinical Trial
por: Zumsteg, Zachary S., et al.
Publicado: (2020)

Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
por: Kunogi, Hiroaki, et al.
Publicado: (2020)

Differences in rates of pelvic lymph node dissection in National Comprehensive Cancer Network favorable, unfavorable intermediate- and high-risk prostate cancer across United States SEER registries
por: Flammia, Rocco Simone, et al.
Publicado: (2022)

Favorable intermediate risk prostate cancer with biopsy Gleason score of 6
por: Oh, Jong Jin, et al.
Publicado: (2021)

Endogenous testosterone density predicts unfavorable disease at final pathology in intermediate risk prostate cancer
por: Porcaro, Antonio Benito, et al.
Publicado: (2021)

Favorable and unfavorable health conditions within OECD countries: An exploratory study
por: Park, Myung-Bae, et al.
Publicado: (2018)

Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis
por: Bernstein, Michael B., et al.
Publicado: (2013)

Unfavorable and favorable changes in modifiable risk factors and incidence of coronary heart disease: The Whitehall II cohort study
por: Virtanen, Marianna, et al.
Publicado: (2018)

Associations of multimorbidity and patient‐reported experiences of care with conservative management among elderly patients with localized prostate cancer
por: Fiano, Ryan M., et al.
Publicado: (2020)

Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution
por: Anderson, Elliot, et al.
Publicado: (2021)

Quality of life of men treated with brachytherapies for prostate cancer
por: Lev, Elise L, et al.
Publicado: (2004)

Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy
por: Dattoli, Michael, et al.
Publicado: (2010)

Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer
por: Muralidhar, Vinayak, et al.
Publicado: (2016)

Clinical outcomes of low-dose-rate brachytherapy based radiotherapy for intermediate risk prostate cancer
por: Okamoto, Keisei, et al.
Publicado: (2020)

Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer
por: Moll, Matthias, et al.
Publicado: (2021)

Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer
por: Kang, Ho Won, et al.
Publicado: (2016)

Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma
por: Schulte, Johannes H., et al.
Publicado: (2010)

Favoring the unfavored: Selective electrochemical nitrogen fixation using a reticular chemistry approach
por: Lee, Hiang Kwee, et al.
Publicado: (2018)

Differential Expression of DNA Repair Genes in Prognostically-Favorable versus Unfavorable Uveal Melanoma
por: Dogrusöz, Mehmet, et al.
Publicado: (2019)

More than Meets the Eye: Understanding Perceptions of China Beyond the Favorable–Unfavorable Dichotomy
por: Li, Xiaojun
Publicado: (2021)

Estrogen Receptor β Expression and Its Clinical Implication in Breast Cancers: Favorable or Unfavorable?
por: Choi, Young
Publicado: (2022)

Commentary on “Clinical implications of endogenous testosterone density in prostate cancer progression in patients with favorable low and intermediate risk treated with radical prostatectomy”
por: Busetto, Gian Maria, et al.
Publicado: (2023)

Clinical implications of endogenous testosterone density on prostate cancer progression in patients with very favorable low and intermediate risk treated with radical prostatectomy
por: Porcaro, Antonio Benito, et al.
Publicado: (2023)

Ten‐step method of high‐dose LDR (125)I brachytherapy for intermediate‐risk prostate cancer
por: Okamoto, Keisei
Publicado: (2021)

A modeling study to estimate prostate cancer‐specific mortality on active surveillance for men with favorable intermediate‐risk prostate cancer: Results from the SEARCH cohort
por: Kuhlmann, Paige K., et al.
Publicado: (2023)

High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort
por: Marotte, Delphine, et al.
Publicado: (2022)

Trimodal therapy with high-dose-rate brachytherapy and hypofractionated external beam radiation combined with long-term androgen deprivation for unfavorable-risk prostate cancer
por: Mori, Keiichiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ds3lluigssi9od55mta7ad5hq1